Great to see the growth from the team and de-risking that happened over the year.
Start of 2021:
-1 asset
-1 clinical program
-1 disease area
-Share price: 36 cents
Today:
-7 assets
-8 clinical programs
-10 disease areas
-Share price: 21.5 cents
I think it is a bargain at these prices. Another example of the Aussie market not understanding biotechs, and the typical investor not having the patience for biotechs. DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $50.77K | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2602327 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18629873 | 23 |
View Market Depth
| Last trade - 15.15pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |